Role of endocannabinoids and endovanilloids in Ca2+ signalling

Cell Calcium

Volumn 45, Issue 6, 2009, Pages 611-624

  De Petrocellis, Luciano ^a   Di Marzo, Vincenzo ^a  

^a Institute of Biomolecular Chemistry   (Italy)

Author keywords

12 HPETE; 2 Arachidonoylglycerol; Anandamide; Apoptosis; Cannabinoid; CB1; CB2; Diabetes; N oleoylethanolamine; Neuromodulators; Neurotransmission; Obesity; Receptor; TRPV1

Indexed keywords

4 AMINOBUTYRIC ACID; ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONATE 12 LIPOXYGENASE; CALCINEURIN; CALCITONIN GENE RELATED PEPTIDE; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CAPSAICIN; CASPASE 3; CATECHOL METHYLTRANSFERASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTATHIONE; INSULIN; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N OLEOYLETHANOLAMINE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; PHOSPHOLIPASE C BETA; PROTEIN KINASE C; SUBSTANCE P; UNINDEXED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1;

ADIPOCYTE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL FATE; CHANNEL GATING; DIABETES MELLITUS; DRUG MECHANISM; HUMAN; INSULIN RELEASE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 67349203919     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2009.03.003     Document Type: Review

References (182)

1. Di Marzo V., and Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostagland. Leukot. Essent. Fatty Acids 53 (1995) 1-11
2. Di Marzo V., Bisogno T., and De Petrocellis L. Anandamide: some like it hot. Trends Pharmacol. Sci. 22 (2001) 346-349
3. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
4. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
5. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
6. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
7. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18 (2007) 129-140
8. Starowicz K., Nigam S., and Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 114 (2007) 13-33
9. Howlett A.C. Cannabinoid receptor signalling. Handb. Exp. Pharmacol. 168 (2005) 53-79
10. Latorre R., Brauchi S., Orta G., Zaelzer C., and Vargas G. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium 42 (2007) 427-438
11. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., and Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 163 (2003) 463-468
12. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., and Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8400-8405
13. Hwang S.W., Cho H., Kwak J., Lee S.Y., Kang C.J., Jung J., Cho S., Min K.H., Suh Y.G., Kim D., and Oh U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6155-6160
14. Vellani V., Petrosino S., De Petrocellis L., Valenti M., Prandini M., Magherini P.C., McNaughton P.A., and Di Marzo V. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology 55 (2008) 1274-1279
15. 2+-independent phospholipase A2 in cell growth and signalling. Biochem. Pharmacol. 76 (2008) 1059-1067
16. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
17. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., and Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281 (2006) 36569-36578
18. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., and Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 280 (2005) 11082-11092
19. Blankman J.L., Simon G.M., and Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007) 1347-1356
20. Prusakiewicz J.J., Turman M.V., Vila A., Ball H.L., Al-Mestarihi A.H., Di Marzo V., and Marnett L.J. Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases. Arch. Biochem. Biophys. 464 (2007) 260-268
21. Canals S., Casarejos M.J., de Bernardo S., Rodríguez-Martín E., and Mena M.A. Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. J. Biol. Chem. 278 (2003) 21542-21549
22. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., and Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301 (2002) 1020-1024
23. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513 (2002) 294-298
24. Mackie K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 20 (2008) 10-14
25. Starowicz K., Cristino L., and Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 14 (2008) 42-54
26. Gunthorpe M.J., and Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des. 14 (2008) 32-41
27. Ahluwalia J., Urban L., Bevan S., and Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci. 17 (2003) 2611-2618
28. Price T.J., Patwardhan A., Akopian A.N., Hargreaves K.M., and Flores C.M. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br. J. Pharmacol. 141 (2004) 1118-1130
29. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
30. Starowicz K., Maione S., Cristino L., Palazzo E., Marabese I., Rossi F., de Novellis V., and Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 27 (2007) 13739-13749
31. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., and Di Marzo V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34 (2009) 593-606
32. Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y., Birch R., Benham C., Bountra C., Chessell I.P., and Anand P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 138 (2008) 667-680
33. Rossi F., Siniscalco D., Luongo L., De Petrocellis L., Bellini G., Petrosino S., Torella M., Santoro C., Nobili B., Perrotta S., Di Marzo V., and Maione S. The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption. Bone 44 (2009) 476-484
34. Hermann H., De Petrocellis L., Bisogno T., Schiano Moriello A., Lutz B., and Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell. Mol. Life Sci. 60 (2003) 607-616
35. Kim S.R., Lee D.Y., Chung E.S., Oh U.T., Kim S.U., and Jin B.K. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J. Neurosci. 25 (2005) 662-671
36. Evans R.M., Scott R.H., and Ross R.A. Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk. Br. J. Pharmacol. 152 (2007) 404-413
37. Kim S.R., Bok E., Chung Y.C., Chung E.S., and Jin B.K. Interactions between CB(1) receptors and TRPV1 channels mediated by 12-HPETE are cytotoxic to mesencephalic dopaminergic neurons. Br. J. Pharmacol. 155 (2008) 253-264
38. Cristino L., Starowicz K., De Petrocellis L., Morishita J., Ueda N., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151 (2008) 955-968
39. Katona I., and Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14 (2008) 923-930
40. Twitchell W., Brown S., and Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78 (1997) 43-50
41. 2+ channel current. Am. J. Physiol. 276 (1999) H2085-2093
42. Chad J., Kalman D., and Armstrong D. The role of cyclic AMP-dependent phosphorylation in the maintenance and modulation of voltage-activated calcium channels. Soc. Gen. Physiol. Ser. 42 (1987) 167-186
43. Yang S.N., Yu J., Mayr G.W., Hofmann F., Larsson O., and Berggren P.O. Inositol hexakisphosphate increases L-type Ca2+ channel activity by stimulation of adenyl cyclase. FASEB J. 15 (2001) 1753-1763
44. Wicher D. Peptidergic modulation of insect voltage-gated Ca(2+) currents: role of resting Ca(2+) current and protein kinases A and C. J. Neurophysiol. 86 (2001) 2353-2362
45. Talavera K., and Nilius B. Biophysics and structure-function relationship of T-type Ca2+ channels. Cell Calcium 40 (2006) 97-114
46. Azad S.C., Kurz J., Marsicano G., Lutz B., Zieglgänsberger W., and Rammes G. Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdale. Learn. Mem. 15 (2008) 143-152
47. Di Marzo V., Galadari S.H., Tippins J.R., and Morris H.R. Interactions between second messengers: cyclic AMP and phospholipase A2- and phospholipase C-metabolites. Life Sci. 49 (1991) 247-259
48. + channels. Receptors Channels 6 (1999) 363-374
49. Lauckner J.E., Hille B., and Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 19144-19149
50. Delmas P., Coste B., Gamper N., and Shapiro M.S. Phosphoinositide lipid second messengers: new paradigms for calcium channel modulation. Neuron 47 (2005) 179-182
51. Michailidis I.E., Zhang Y., and Yang J. The lipid connection-regulation of voltage-gated Ca(2+) channels by phosphoinositides. Pflugers Arch. 455 (2007) 147-155
52. Nilius B., Owsianik G., and Voets T. Transient receptor potential channels meet phosphoinositides. EMBO J. 27 (2008) 2809-2816
53. Gómez del Pulgar T., Velasco G., and Guzmán M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347 (2000) 369-373
54. Sánchez M.G., Ruiz-Llorente L., Sánchez A.M., and Díaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 15 (2003) 851-859
55. Ellert-Miklaszewska A., Kaminska B., and Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 17 (2005) 25-37
56. Kawanabe Y., Hashimoto N., and Masaki T. Role of phosphoinositide 3-kinase in the nonselective cation channel activation by endothelin-1/endothelinB receptor. Am. J. Physiol. Cell Physiol. 284 (2003) C506-510
57. Viard P., Butcher A.J., Halet G., Davies A., Nürnberg B., Heblich F., and Dolphin A.C. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat. Neurosci. 7 (2004) 939-946
58. Stefano G.B., Esch T., Cadet P., Zhu W., Mantione K., and Benson H. Endocannabinoids as autoregulatory signaling molecules: coupling to nitric oxide and a possible association with the relaxation response. Med. Sci. Monit. 9 (2003) RA63-75
59. Sergeeva O.A., Doreulee N., Chepkova A.N., Kazmierczak T., and Haas H.L. Long-term depression of cortico-striatal synaptic transmission by DHPG depends on endocannabinoid release and nitric oxide synthesis. Eur. J. Neurosci. 26 (2007) 1889-1894
60. Grassi C., D'Ascenzo M., and Azzera G.B. Modulation of Ca(v)1 and Ca(v)2.2 channels induced by nitric oxide via cGMP-dependent protein kinase. Neurochem. Int. 45 (2004) 885-893
61. Liu Z., Xu J.G., Zhang H., Fang Y.J., and Mei Y.A. C(6)-ceramide inhibited Na(+) currents by intracellular Ca(2+) release in rat myoblasts. J. Cell. Physiol. 213 (2007) 151-160
62. Masgrau R., Hurel C., Papastefanaki F., Georgopoulou N., Thomaidou D., and Matsas R. BM88/Cend1 regulates stimuli-induced intracellular calcium mobilization. Neuropharmacology 3 (2009) 598-609
63. Mackie K., Lai Y., Westenbroek R., and Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15 (1995) 6552-6561
64. De Petrocellis L., Marini P., Matias I., Schiano Moriello A., Starowicz K., Cristino L., Nigam S., and Di Marzo V. Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Exp. Cell. Res. 313 (2007) 2993-3004
65. Sugiura T., Kodaka T., Kondo S., Tonegawa T., Nakane S., Kishimoto S., Yamashita A., and Waku K. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma × glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 229 (1996) 58-64
66. P. Marini, A. Schiano Moriello, L. Cristino, M. Palmery, L. De Petrocellis, V. Di Marzo, Cannabinoid CB1 receptor effects on intracellular calcium in SH-SY5Y cells: interactions with the muscarinic receptor and the δ-opioid receptor, submitted for publication.
67. Venkatachalam K., and Montell C. TRP channels. Annu. Rev. Biochem. 76 (2007) 387-417
68. Vennekens R., Owsianik G., and Nilius B. Vanilloid transient receptor potential cation channels: an overview. Curr. Pharm. Des. 14 (2008) 18-31
69. De Petrocellis L., Bisogno T., Maccarrone M., Davis J.B., Finazzi-Agrò A., and Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276 (2001) 12856-12863
70. Jordt S.E., and Julius D. Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell 108 (2002) 421-430
71. Appendino G., Minassi A., Pagani A., and Ech-Chahad A. The role of natural products in the ligand deorphanization of TRP channels. Curr. Pharm. Des. 14 (2008) 2-17
72. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140 (2003) 790-801
73. De Petrocellis L., Davis J.B., and Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506 (2001) 253-256
74. Lazar J., Braun D.C., Tóth A., Wang Y., Pearce L.V., Pavlyukovets V.A., Blumberg P.M., Garfield S.H., Wincovitch S., Choi H.K., and Lee J. Kinetics of penetration influence the apparent potency of vanilloids on TRPV1. Mol. Pharmacol. 69 (2006) 1166-1173
75. Mohapatra D.P., and Nau C. Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J. Biol. Chem. 280 (2005) 13424-13432
76. Vellani V., Mapplebeck S., Moriondo A., Davis J.B., and McNaughton P.A. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and Anandamide. J. Physiol. 534 (2001) 813-825
77. De Petrocellis L., Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., Creminon C., Davis J.B., Geppetti P., and Di Marzo V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem. 77 (2001) 1660-1663
78. van der Stelt M., Trevisani M., Vellani V., De Petrocellis L., Schiano Moriello A., Campi B., McNaughton P., Geppetti P., and Di Marzo V. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24 (2005) 3026-3037
79. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., and Fernandez-Ruiz J.J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. 420 (2001) 123-131
80. Ahluwalia J., Yaqoob M., Urban L., Bevan S., and Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J. Neurochem. 84 (2003) 585-591
81. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., and Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 26 (2006) 6643-6650
82. Liu M., Liu M.C., Magoulas C., Priestley J.V., and Willmott N.J. Versatile regulation of cytosolic Ca2+ by vanilloid receptor I in rat dorsal root ganglion neurons. J. Biol. Chem. 278 (2003) 5462-5472
83. Turner H., Fleig A., Stokes A., Kinet J.P., and Penner R. Discrimination of intracellular calcium store subcompartments using TRPV1 (transient receptor potential channel, vanilloid subfamily member release channel activity. Biochem. J. 371 (2003) 341-350
84. Xin H., Tanaka H., Yamaguchi M., Takemori S., Nakamura A., and Kohama K. Vanilloid receptor expressed in the sarcoplasmic reticulum of rat skeletal muscle. Biochem. Biophys. Res. Commun. 332 (2005) 756-762
85. Di Marzo V., and Cristino L. Why endocannabinoids are not all alike. Nat. Neurosci. 11 (2008) 124-126
86. Hillard C.J., and Jarrahian A. Accumulation of anandamide: evidence for cellular diversity. Neuropharmacology 48 (2005) 1072-1078
87. Adermark L., and Lovinger D.M. Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 20564-20569
88. Fioravanti B., De Felice M., Stucky C.L., Medler K.A., Luo M.C., Gardell L.R., Ibrahim M., Malan Jr. T.P., Yamamura H.I., Ossipov M.H., King T., Lai J., Porreca F., and Vanderah T.W. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J. Neurosci. 28 (2008) 11593-11602
89. Voets T., Droogmans G., Wissenbach U., Janssens A., Flockerzi V., and Nilius B. The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature 430 (2004) 748-754
90. Wu Z.Z., Chen S.R., and Pan H.L. Transient receptor potential vanilloid type 1 activation down-regulates voltage-gated calcium channels through calcium-dependent calcineurin in sensory neurons. J. Biol. Chem. 280 (2005) 18142-18151
91. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., and Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11 (2008) 152-159
92. De Petrocellis L., Deva R., Manieri F., Schaefer M., Bisogno T., Ciccoli R., Ligresti A., Hill K., Nigam S., Appendino G., and Di Marzo V. Biotransformation of anandamide by an unicellular fungus and chemical synthesis and pharmacological characterization and of the resulting 3-hydroxy-derivative. J. Lipid Res. 50 4 (2009) 658-666
93. Matias I., Chen J., De Petrocellis L., Bisogno T., Ligresti A., Fezza F., Krauss A.H., Shi L., Protzman C.E., Li C., Liang Y., Nieves A.L., Kedzie K.M., Burk R.M., Di Marzo V., and Woodward D.F. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther. 309 (2004) 745-757
94. De Petrocellis L., Starowicz K., Schiano Moriello A., Vivese M., Orlando P., and Di Marzo V. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp. Cell. Res. 313 (2007) 1911-1920
95. McKemy D.D. How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol. Pain 1 (2005) 16
96. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30 3 (2009) 156-163
97. Lacinová L. Pharmacology of recombinant low-voltage activated calcium channels. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 105-111
98. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., and Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20 (2001) 7033-7040
99. Chemin J., Nargeot J., and Lory P. Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J. Biol. Chem. 282 (2007) 2314-2323
100. H.R. Ross, A.J. Gilmore, M. Connor, Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine, Br. J. Pharmacol., in press.
101. Fisyunov A., Tsintsadze V., Min R., Burnashev N., and Lozovaya N. Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons. J. Neurophysiol. 96 (2006) 1267-1277
102. Johnson D.E., Heald S.L., Dally R.D., and Janis R.A. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostagland. Leukot. Essent. Fatty Acids 48 (1993) 429-437
103. Shimasue K., Urushidani T., Hagiwara M., and Nagao T. Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel. Eur. J. Pharmacol. 296 (1996) 347-350
104. Köfalvi A., Pereira M.F., Rebola N., Rodrigues R.J., Oliveira C.R., and Cunha R.A. Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. Br. J. Pharmacol. 151 (2007) 551-563
105. Ferreira S.G., Lomaglio T., Avelino A., Cruz F., Oliveira C.R., Cunha R.A., and Köfalvi A. N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology 56 (2009) 676-683
106. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., and Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of Anandamide. Nature 400 (1999) 452-457
107. Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P., and Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 21 (2001) 1104-1109
108. Shin J., Cho H., Hwang S.W., Jung J., Shin C.Y., Lee S.Y., Kim S.H., Lee M.G., Choi Y.H., Kim J., Haber N.A., Reichling D.B., Khasar S., Levine J.D., and Oh U. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10150-10155
109. O'Sullivan S.E., Kendall D.A., and Randall M.D. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br. J. Pharmacol. 141 (2004) 803-812
110. Zhong B., and Wang D.H. N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H728-735
111. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1998) 111-119
112. Helyes Z., Németh J., Thán M., Bölcskei K., Pintér E., and Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci. 73 (2003) 2345-2353
113. Tucker R.C., Kagaya M., Page C.P., and Spina D. The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br. J. Pharmacol. 132 (2001) 1127-1135
114. Harrison S., De Petrocellis L., Trevisani M., Benvenuti F., Bifulco M., Geppetti P., and Di Marzo V. Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. Eur. J. Pharmacol. 475 (2003) 107-114
115. Jia Y., McLeod R.L., Wang X., Parra L.E., Egan R.W., and Hey J.A. Anandamide induces cough in conscious guinea-pigs through VR1 receptors. Br. J. Pharmacol. 137 (2002) 831-836
116. Dinis P., Charrua A., Avelino A., Yaqoob M., Bevan S., Nagy I., and Cruz F. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J. Neurosci. 24 (2004) 11253-11263
117. Calignano A., Kátona I., Désarnaud F., Giuffrida A., La Rana G., Mackie K., Freund T.F., and Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408 (2000) 96-101
118. Yoshihara S., Morimoto H., Ohori M., Yamada Y., Abe T., and Arisaka O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int. Arch. Allergy Immunol. 138 (2005) 80-87
119. García Mdel C., Adler-Graschinsky E., and Celuch S.M. Role of CGRP and GABA in the hypotensive effect of intrathecally administered anandamide to anesthetized rats. Eur. J. Pharmacol. 532 (2006) 88-98
120. Li J., Kaminski N.E., and Wang D.H. Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41 (2003) 757-762
121. Wang Y., Kaminski N.E., and Wang D.H. Endocannabinoid regulates blood pressure via activation of the transient receptor potential vanilloid type 1 in Wistar rats fed a high-salt diet. J. Pharmacol. Exp. Ther. 321 (2007) 763-769
122. Lake K.D., Martin B.R., Kunos G., and Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29 (1997) 1204-1210
123. Bátkai S., Pacher P., Osei-Hyiaman D., Radaeva S., Liu J., Harvey-White J., Offertáler L., Mackie K., Rudd M.A., Bukoski R.D., and Kunos G. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110 (2004) 1996-2002
124. Kelly S., and Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J. Neurophysiol. 86 (2001) 3061-3064
125. Jennings E.A., Vaughan C.W., Roberts L.A., and Christie M.J. The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro. J. Physiol. 548 (2003) 121-129
126. Zhou H.Y., Chen S.R., Chen H., and Pan H.L. The glutamatergic nature of TRPV1-expressing neurons in the spinal dorsal horn. J. Neurochem. 108 (2009) 305-318
127. Morisset V., Ahluwalia J., Nagy I., and Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur. J. Pharmacol. 429 (2001) 93-100
128. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., Petrosino S., Guglielmotti V., Rossi F., and Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316 (2006) 969-982
129. Palazzo E., Rossi F., and Maione S. Role of TRPV1 receptors in descending modulation of pain. Mol. Cell. Endocrinol. 286 (2008) S79-83
130. Derbenev A.V., Stuart T.C., and Smith B.N. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J. Physiol. 559 (2004) 923-938
131. Derbenev A.V., Monroe M.J., Glatzer N.R., and Smith B.N. Vanilloid-mediated heterosynaptic facilitation of inhibitory synaptic input to neurons of the rat dorsal motor nucleus of the vagus. J. Neurosci. 26 (2006) 9666-9672
132. Sharkey K.A., Cristino L., Oland L.D., Van Sickle M.D., Starowicz K., Pittman Q.J., Guglielmotti V., Davison J.S., and Di Marzo V. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 25 (2007) 2773-2782
133. Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M.T., van der Stelt M., Bernardi G., Molinari M., Maccarrone M., and Mercuri N.B. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 (2007) 298-308
134. Musella A., De Chiara V., Rossi S., Prosperetti C., Bernardi G., Maccarrone M., and Centone D. TRPV1 channels facilitate glutamate transmission in the striatum. Mol. Cell. Neurosci. 40 (2009) 89-97
135. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., and Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 1007 (2004) 152-159
136. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682
137. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68 (2002) 247-286
138. Marinelli S., Pacioni S., Bisogno T., Di Marzo V., Prince D.A., Huguenard J.R., and Bacci A. The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J. Neurosci. 28 (2008) 13532-13541
139. Gibson H.E., Edwards J.G., Page R.S., Van Hook M.J., and Kauer J.A. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57 (2008) 746-759
140. Marsch R., Foeller E., Rammes G., Bunck M., Kössl M., Holsboer F., Zieglgänsberger W., Landgraf R., Lutz B., and Wotjak C.T. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J. Neurosci. 27 (2007) 832-839
141. Li H.B., Mao R.R., Zhang J.C., Yang Y., Cao J., and Xu L. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiatry 64 (2008) 286-292
142. Feinmark S.J., Begum R., Tsvetkov E., Goussakov I., Funk C.D., Siegelbaum S.A., and Bolshakov V.Y. 12-lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses. J. Neurosci. 23 (2003) 11427-11435
143. S. Maione, L. Cristino, A.L. Migliozzi, A.L Georgiou, K. Starowicz, T.E Salt and V. Di Marzo TRPV1 channels control synaptic plasticity in the developing superior colliculus, J Physiol. submitted for publication.
144. Di Marzo V., Gobbi G., and Szallasi A. Brain TRPV1: a depressing TR(i)P down memory lane?. Trends Pharmacol. Sci. 29 (2008) 594-600
145. Lizanecz E., Bagi Z., Pásztor E.T., Papp Z., Edes I., Kedei N., Blumberg P.M., and Tóth A. Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Mol. Pharmacol. 69 (2006) 1015-1023
146. Horvath G., Kekesi G., Nagy E., and Benedek G. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain 134 (2008) 277-284
147. Veldhuis W.B., van der Stelt M., Wadman M.W., van Zadelhoff G., Maccarrone M., Fezza F., Veldink G.A., Vliegenthart J.F., Bär P.R., Nicolay K., and Di Marzo V. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23 (2003) 4127-4133
148. Pegorini S., Braida D., Verzoni C., Guerini-Rocco C., Consalez G.G., Croci L., and Sala M. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br. J. Pharmacol. 144 (2005) 727-735
149. Galve-Roperh I., Aguado T., Palazuelos J., and Guzmán M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 14 (2008) 2279-2288
150. Kim S.R., Chung Y.C., Chung E.S., Park K.W., Won S.Y., Bok E., Park E.S., and Jin B.K. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol. Neurobiol. 35 (2007) 245-254
151. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., Childs J., and Greenberg D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 66 (2004) 204-208
152. Cernak I., Vink R., Natale J., Stoica B., Lea IV P.M., Movsesyan V., Ahmed F., Knoblach S.M., Fricke S.T., and Faden A.I. The "dark side" of endocannabinoids: a neurotoxic role for Anandamide. J. Cereb. Blood Flow Metab. 24 (2004) 564-578
153. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51 (2008) 1356-1367
154. Matias I., Petrosino S., Racioppi A., Capasso R., Izzo A.A., and Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol. Cell. Endocrinol. 286 (2008) S66-78
155. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 18 (2007) 27-37
156. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91 (2006) 3171-3180
157. Bellocchio L., Cervino C., Vicennati V., Pasquali R., and Pagotto U. Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. J. Neuroendocrinol. 20 (2008) 130-138
158. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., and Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
159. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., D'Esposito V., Beguinot F., Formisano P., and Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol. Pharmacol. 74 (2008) 1678-1686
160. Eckardt K., Sell H., Taube A., Koenen M., Platzbecker B., Cramer A., Horrighs A., Lehtonen M., Tennagels N., and Eckel J. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 52 (2009) 664-674
161. Suri A., and Szallasi A. The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol. Sci. 29 (2008) 29-36
162. Zhang L.L., Yan Liu D., Ma L.Q., Luo Z.D., Cao T.B., Zhong J., Yan Z.C., Wang L.J., Zhao Z.G., Zhu S.J., Schrader M., Thilo F., Zhu Z.M., and Tepel M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ. Res. 100 (2007) 1063-1070
163. Motter A.L., and Ahern G.P. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett. 582 (2008) 2257-2262
164. Wang X., Miyares R.L., and Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J. Physiol. 564 (2005) 541-547
165. Thabuis C., Tissot-Favre D., Bezelgues J.B., Martin J.C., Cruz-Hernandez C., Dionisi F., and Destaillats F. Biological functions and metabolism of oleoylethanolamide. Lipids 43 (2008) 887-894
166. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 423-431
167. Akiba Y., Kato S., Katsube K., Nakamura M., Takeuchi K., Ishii H., and Hibi T. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem. Biophys. Res. Commun. 321 (2004) 219-225
168. Juan-Picó P., Fuentes E., Bermúdez-Silva F.J., Javier Díaz-Molina F., Ripoll C., Rodríguez de Fonseca F., and Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
169. Nakata M., and Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul. Pept. 145 (2008) 49-53
170. Starowicz K.M., Cristino L., Matias I., Capasso R., Racioppi A., Izzo A.A., and Di Marzo V. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16 (2008) 553-565
171. Laychock S.G., Hoffman J.M., Meisel E., and Bilgin S. Pancreatic islet arachidonic acid turnover and metabolism and insulin release in response to delta-9-tetrahydrocannabinol. Biochem. Pharmacol. 35 (1986) 2003-2008
172. Bermúdez-Silva F.J., Suárez J., Baixeras E., Cobo N., Bautista D., Cuesta-Muñoz A.L., Fuentes E., Juan-Pico P., Castro M.J., Milman G., Mechoulam R., Nadal A., and Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51 (2008) 476-487
173. Gram D.X., Ahrén B., Nagy I., Olsen U.B., Brand C.L., Sundler F., Tabanera R., Svendsen O., Carr R.D., Santha P., Wierup N., and Hansen A.J. Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. Eur. J. Neurosci. 25 (2007) 213-223
174. Razavi R., Chan Y., Afifiyan F.N., Liu X.J., Wan X., Yantha J., Tsui H., Tang L., Tsai S., Santamaria P., Driver J.P., Serreze D., Salter M.W., and Dosch H.M. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 127 (2006) 1123-1135
175. van der Stelt M., and Di Marzo V. Anandamide as an intracellular messenger regulating ion channel activity. Prostagland. Other Lipid Mediat. 77 (2005) 111-122
176. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br. J. Pharmacol. 148 (2006) 123-135
177. Movsesyan V.A., Stoica B.A., Yakovlev A.G., Knoblach S.M., Lea IV P.M., Cernak I., Vink R., and Faden A.I. Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 11 (2004) 1121-1132
178. Siegmund S.V., Uchinami H., Osawa Y., Brenner D.A., and Schwabe R.F. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41 (2005) 1085-1095
179. Bentzen P.J., and Lang F. Effect of anandamide on erythrocyte survival. Cell Physiol. Biochem. (2007) 1033-1042
180. Maccarrone M., Lorenzon T., Bari M., Melino G., and Finazzi-Agrò A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275 (2000) 31938-31945
181. Kim S.R., Kim S.U., Oh U., and Jin B.K. Transient receptor potential vanilloid subtype 1 mediates microglial cell death in vivo and in vitro via Ca2+-mediated mitochondrial damage and cytochrome c release. J. Immunol. 177 (2006) 4322-4329
182. Amantini C., Mosca M., Nabissi M., Lucciarini R., Caprodossi S., Arcella A., Giangaspero F., and Santoni G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem. 102 (2007) 977-990